Glyphosate \[*N*-(phosphonomethyl)glycine\], commonly sold in the commercial formulation named Roundup (Monsanto Company, St. Louis, MO), has been a frequently used herbicide on both cropland and noncropland areas of the world since its introduction in the 1970s ([@b55-ehp0113-000049]). Roundup is a combination of the active ingredient and other chemicals, including a surfactant (poly-oxyethyleneamine) that enhances the spreading of spray droplets when they contact foliage. Glyphosate is a broad-spectrum herbicide of which the primary mechanism is inhibition of the enzyme 5-enolpyruvoyl-shikimate 3-phosphate synthase, which is essential for the formation of aromatic amino acids in plants ([@b47-ehp0113-000049]). Because this specific biologic pathway operates only in plants and microorganisms, the mechanism is not considered to be a risk for humans. Nevertheless, genotoxic, hormonal, and enzymatic effects in mammals have been reported (Bolognesi et al. 1997; [@b10-ehp0113-000049]; [@b15-ehp0113-000049]; [@b25-ehp0113-000049]; [@b30-ehp0113-000049], [@b31-ehp0113-000049]; [@b40-ehp0113-000049]; [@b43-ehp0113-000049]; [@b51-ehp0113-000049]; [@b56-ehp0113-000049]).

Results from genotoxicity studies of glyphosate have been conflicting. Glyphosate did not show any genotoxic activity in a battery of assays ([@b21-ehp0113-000049]; [@b22-ehp0113-000049]; [@b29-ehp0113-000049]; [@b54-ehp0113-000049]). However, other studies observed that glyphosate treatment of human lymphocytes *in vitro* resulted in increased sister chromatid exchanges (Bolognesi et al. 1997), chromosomal aberrations ([@b31-ehp0113-000049]), and indicators of oxidative stress ([@b31-ehp0113-000049]). Some studies found slightly greater toxicity of the Roundup formulation compared with glyphosate, in terms of both acute toxicity ([@b19-ehp0113-000049]; [@b32-ehp0113-000049]; [@b34-ehp0113-000049]) and genotoxicity (Bolognesi et al. 1997; [@b50-ehp0113-000049]). Roundup was associated with increased DNA adducts in mice ([@b43-ehp0113-000049]) and a weak mutagenic effect in the *Salmonella* assay ([@b27-ehp0113-000049]; [@b35-ehp0113-000049]; [@b45-ehp0113-000049]), whereas glyphosate alone did not show these effects. Chronic feeding studies of glyphosate have not provided evidence of a carcinogenic effect in mice or rats ([@b55-ehp0113-000049]).

The U.S. Environmental Protection Agency ([@b48-ehp0113-000049]) and the World Health Organization ([@b53-ehp0113-000049]) reviewed the toxicology data on glyphosate and concluded that glyphosate is not mutagenic or carcinogenic. The U.S. EPA classified glyphosate as category E, indicating "evidence of noncarcinogenicity for humans" ([@b53-ehp0113-000049]). Despite this conclusion, three recent case--control studies suggested an association between reported glyphosate use and the risk of non-Hodgkin lymphoma (NHL) ([@b12-ehp0113-000049]; [@b23-ehp0113-000049]; [@b24-ehp0113-000049]; [@b33-ehp0113-000049]). Considering the widespread and frequent use of glyphosate in both the United States and the rest of the world, ongoing risk assessment is of importance. We studied site-specific cancer incidence associated with glyphosate use among pesticide applicators in the Agricultural Health Study (AHS) cohort.

Materials and Methods
=====================

Cohort enrollment and follow-up.
--------------------------------

The AHS is a prospective cohort study in Iowa and North Carolina, which includes 57,311 private and commercial applicators who were licensed to apply restricted-use pesticides at the time of enrollment. Recruitment of the applicators occurred between 1993 and 1997 ([@b1-ehp0113-000049]). Cohort members were matched to cancer registry files in Iowa and North Carolina for case identification and to the state death registries and the National Death Index ([@b38-ehp0113-000049]) to ascertain vital status. Incident cancers were identified for the time period from the date of enrollment until 31 December 2001 and were coded according to the *International Classification of Diseases,* 9th Revision ([@b52-ehp0113-000049]). If cohort members had moved from the state, they were censored in the year they left. The median time of follow-up was 6.7 years.

Exposure assessment.
--------------------

Using a self-administered enrollment questionnaire, we collected comprehensive-use data on 22 pesticides, ever/never use information for 28 additional pesticides, and general information on pesticide application methods, personal protective equipment, pesticide mixing, and equipment repair. Data were also collected on basic demographic and lifestyle factors. Applicators who completed this questionnaire were given a self-administered take-home questionnaire, which contained additional questions on occupational exposures and lifestyle factors. The questionnaires are available from the AHS website ([@b39-ehp0113-000049]).

We constructed three glyphosate exposure metrics for this analysis: *a*) ever personally mixed or applied products containing glyphosate (ever/never); *b*) cumulative lifetime days of use, or "cumulative exposure days" (years of use × days per year, categorized in tertiles among users: 1--20, 21--56, 57--2,678); and *c*) intensity-weighted cumulative exposure days (years of use × days per year × intensity level, categorized in tertiles: 0.1--79.5, 79.6--337.1, 337.2--18,241). Tertiles were chosen *a priori* as the cut points with which to categorize exposure data, to avoid sparse data for rare cancers in the high-exposure categories. Intensity levels were estimated using questionnaire data from enrollment and measurement data from the published pesticide exposure literature, as follows: intensity level = \[(mixing status + application method + equipment repair status) × personal protective equipment use\] ([@b13-ehp0113-000049]).

Data analysis.
--------------

Persons whose first primary cancer occurred before the time of enrollment (*n* = 1,074) were excluded from analyses, as were subjects who were lost to follow-up or otherwise did not contribute any person-time (*n* = 298) and applicators who did not provide any information on age (*n* = 7) or whether they had ever used glyphosate (*n* = 1,678). After exclusions, 54,315 subjects were available for inclusion in the age-adjusted analyses of cancer incidence in relation to glyphosate use; however, other analyses contained fewer observations because of missing data for duration and frequency of glyphosate use or for covariates.

We compared certain baseline characteristics among three types of pesticide applicators: *a*) those applicators who never personally used glyphosate; *b*) applicators with the lowest glyphosate exposure, defined as being in the lowest tertile of cumulative exposure days; and *c*) those with higher glyphosate exposure, defined as being in the middle or highest tertile of cumulative exposure days. The purpose of the comparison was to identify potential confounders of glyphosate exposure--disease associations for the various analyses we conducted. Differences between the exposure groups were tested using the chi-square statistics and associated *p*-values.

Poisson regression analyses were carried out for all cancers combined and specific cancer sites to estimate rate ratios (RRs) and 95% confidence intervals (CIs) associated with glyphosate exposure metrics; the effect of each metric was evaluated in a separate model for each cancer. We analyzed tertile exposure variables in separate models using either the lowest-tertile--exposed or never-exposed subjects as the reference category. We investigated specific cancer sites for which there were at least 30 cases with sufficient information for inclusion in age-adjusted analyses. These cancers were then evaluated for all the exposure metrics and in adjusted analyses, despite smaller numbers of cases upon further adjustment. For each exposure metric, RRs were adjusted for demographic and lifestyle factors, including age at enrollment (continuous), education (dichotomous: ≤high school graduate or GED/education beyond high school), pack-years of cigarette smoking \[indicator variables: never, pack-years at or below the median (12 pack-years), pack-years above the median\], alcohol consumption in the past year \[indicator variables: none, frequency at or below the median (72 drinks), frequency above the median\], family history of cancer in first-degree relatives (dichotomous: yes/no), and state of residence (dichotomous: Iowa/North Carolina). There was insufficient variability in sex or applicator type to adjust for these factors.

Potential confounding from exposure to other pesticides was explored by adjusting for the five pesticides for which cumulative-exposure-day variables were most highly associated with glyphosate cumulative exposure days \[(2,4-dichlorophenoxy)acetic acid (2,4-D), alachlor, atrazine, metolachlor, trifluralin\]; these pesticide exposures were coded as variables indicating never, low, and high, with the split between low and high as the median of their cumulative exposure days. Additionally, of the pesticides for which only ever/never use information was available, we adjusted for the five pesticides that were most highly associated with ever use of glyphosate (benomyl, maneb, paraquat, carbaryl, diazinon). Where inclusion of all 10 other pesticides in a model changed a glyphosate exposure estimate by at least 20% (compared with a model restricted to the same observations), these results were presented as the final results for that cancer; otherwise, estimates adjusted only for demographic and lifestyle factors are presented.

Tests for trend across tertiles were conducted by creating a continuous variable with assigned values equal to the median value of cumulative exposure days (or intensity-weighted exposure days) within each tertile; the *p*-value for the trend test was that from the Poisson model coefficient for this continuous variable. We considered *p*-values \< 0.10 as indicative of a trend.

Additional analyses were conducted for cancers for which we observed elevated RRs, and for NHL because of its association with glyphosate in previous studies. These included analyses stratified by state and analyses across quartiles and quintiles (where numbers allowed) of exposure days metrics.

Results
=======

Selected characteristics of the glyphosate-exposed and never-exposed applicators are presented in [Table 1](#t1-ehp0113-000049){ref-type="table"}. Among 54,315 subjects included in age-adjusted analyses, 41,035 (75.5%) reported having ever personally mixed or applied products containing glyphosate, and 13,280 (24.5%) did not. The cohort, both exposed and never exposed, was composed of primarily of male, middle-aged, private applicators. This is a population with relatively low smoking prevalence; in both the exposed and never-exposed groups, more than half of the subjects reported that they had never smoked. Significant differences (*p* \< 0.05) existed between never-exposed and lowest-exposed subjects for all of the characteristics in [Table 1](#t1-ehp0113-000049){ref-type="table"}. Lowest- and higher-exposed subjects (*p* \< 0.05) also differed on several factors, the most notable being that higher-exposed subjects were more likely to be commercial applicators, to have consumed greater amounts of alcohol in the past year, and to have used other specific pesticides. However, lowest- and higher-exposed subjects were similar to each other (*p* ≥0.05) in characteristics including smoking and family history of cancer in a first-degree relative. In addition, lowest- and higher-exposed subjects were more similar to each other than to their never-exposed counterparts (by qualitative comparison of percentages only) in factors including North Carolina residence, education beyond high school, and use of other pesticides. Because of relative similarities between lowest- and higher-exposed in factors associated with socioeconomic status and other exposures, we decided to conduct some analyses using lowest-exposed rather than never-exposed applicators as the reference group, in order to avoid residual confounding by unmeasured covariates. However, we decided *a priori* that any association should be apparent regardless of which reference group was used.

RRs for the association of all cancers combined and specific cancers with having ever used glyphosate are presented in [Table 2](#t2-ehp0113-000049){ref-type="table"}. RRs adjusted for age only are presented, as well as RRs adjusted for demographic and lifestyle factors and, in some cases, for other pesticides. The incidence of all cancers combined was not associated with glyphosate use, nor were most specific cancers. There was an 80% increased risk of melanoma associated with glyphosate use in the age-adjusted analysis, which diminished slightly upon further adjustment. Adjusted risk estimates for colon, rectum, kidney, and bladder cancers were elevated by 30--60%, but these estimates were not statistically significant. There was more than 2-fold increased risk of multiple myeloma associated with ever use of glyphosate in adjusted analyses, although this is based on a small number of cases. The association between myeloma incidence and glyphosate exposure was consistent in both states (ever used glyphosate, fully adjusted analyses: Iowa RR = 2.6; North Carolina RR = 2.7).

Results from analyses of tertiles of increasing glyphosate exposure level are presented in [Table 3](#t3-ehp0113-000049){ref-type="table"}. A decreased risk of lung cancer was suggested for the highest tertile of both cumulative and intensity-weighted exposure days (*p*-value for trend = 0.02); however, a similar trend was not observed in analyses using never exposed as the referent (results not shown). There was a 40% increased risk of colon cancer for the highest tertile of intensity-weighted exposure; however, no clear monotonic trend was observed for either exposure metric. Elevated risks of leukemia and pancreas cancer were observed only for the middle tertiles of both cumulative and intensity-weighted exposure days, with no increased risk among those with the highest exposure. The associations we observed in the analysis of ever use of glyphosate ([Table 2](#t2-ehp0113-000049){ref-type="table"}) for melanoma, rectum, kidney, and bladder cancers were not confirmed in analyses based on exposure-day metrics; similarly, no exposure--response patterns were observed in analyses using never exposed as the referent or in analyses across quintiles of exposure (results not shown). No association was observed between NHL and glyphosate exposure in any analysis, including an analysis comparing the highest with the lowest quintile of exposure (\> 108 vs. \> 0--9 cumulative exposure days: RR = 0.9; 95% CI, 0.4--2.1).

Elevated RRs were estimated for multiple myeloma, with an approximate 2-fold increased risk for the highest tertile of both cumulative and intensity-weighted exposure days ([Table 3](#t3-ehp0113-000049){ref-type="table"}); however, small numbers precluded precise effect estimation (*n* = 19 in adjusted analyses of exposure-day metrics). The estimated intensity-level component of the intensity-weighted exposure-day metric was not associated with multiple myeloma (highest vs. lowest tertile: RR = 0.6; 95% CI, 0.2--1.8), and observed positive associations of the intensity-weighted exposure-day metric with myeloma relied solely on the exposure-day component; therefore, only results for cumulative exposure days are shown further. When using never exposed as the referent, the association between glyphosate use and multiple myeloma was more pronounced, with more than 4-fold increased risk associated with the highest tertile of cumulative exposure days (tertile 1: RR = 2.3; 95% CI, 0.6--8.9; tertile 2: RR = 2.6; 95% CI, 0.6--11.5; tertile 3: RR = 4.4; 95% CI, 1.0--20.2; *p*-value for trend = 0.09). Although the myeloma cases were sparsely distributed in analyses of quartiles and quintiles, the highest increased risks were observed in the highest exposure categories (full set of results not shown: upper quartile vs. never exposed: RR = 6.6; 95% CI, 1.4--30.6; *p*-value for trend across quartiles = 0.01).

Discussion
==========

There was no association between glyphosate exposure and all cancer incidence or most of the specific cancer subtypes we evaluated, including NHL, whether the exposure metric was ever used, cumulative exposure days, or intensity-weighted cumulative exposure days. The most consistent finding in our study was a suggested association between multiple myeloma and glyphosate exposure, based on a small number of cases.

Although our study relied on self-reported exposure information, farmers have been shown to provide reliable information regarding their personal pesticide use ([@b2-ehp0113-000049]; [@b3-ehp0113-000049]; [@b14-ehp0113-000049]; [@b16-ehp0113-000049]; [@b26-ehp0113-000049]). Investigators have used pesticide supplier reports ([@b3-ehp0113-000049]) and self-reported pesticide use information provided earlier ([@b16-ehp0113-000049]) to assess the validity of retrospectively reported pesticide use data. Among farmers in the AHS, [@b2-ehp0113-000049] reported high reliability for reports of ever use of a particular pesticide (ranging from 70 to \> 90%). Agreement for duration and frequency of use was lower but generally 50--60% for specific pesticides. [@b26-ehp0113-000049] have demonstrated that farmers provide plausible data regarding lifetime duration of use, with fewer than 5% reporting implausible values for specific chemicals.

There were rather few cases of NHL for inclusion in this analysis (*n* = 92); nevertheless, the available data provided evidence of no association between glyphosate exposure and NHL incidence. This conclusion was consistent across analyses using the different exposure metrics and in analyses using either never exposed or low exposed as the referent. Furthermore, there was no apparent effect of glyphosate exposure on the risk of NHL in analyses stratified by state of residence or in analyses of highly exposed groups comparing the highest with the lowest quintile of exposure. These findings conflict with recent studies. The first report of an association of glyphosate with NHL was from a case--control study, but the estimate was based on only four exposed cases ([@b23-ehp0113-000049]). A pooled analysis of this initial study with a study of hairy cell leukemia showed a relationship between glyphosate exposure and an increased risk of disease \[unadjusted analysis: odds ratio (OR) = 3.0; 95% CI, 1.1--8.5\] ([@b24-ehp0113-000049]). A more extensive study conducted across a large region of Canada found an elevated risk of NHL associated with glyphosate use more frequent than 2 days/year (OR = 2.1; 95% CI, 1.2--3.7) ([@b33-ehp0113-000049]). Similarly, increased NHL risk in men was associated with having ever used glyphosate (OR = 2.1; 95% CI, 1.1--4.0) after adjustment for other commonly used pesticides in a pooled analysis of National Cancer Institute--sponsored case--control studies conducted in Nebraska, Kansas, Iowa, and Minnesota ([@b12-ehp0113-000049]). These previous studies were retrospective in design and thereby potentially susceptible to recall bias of exposure reporting. Our analysis of the AHS cohort had a prospective design, which should largely eliminate the possibility of recall bias. Differences in recall bias could account for discrepant study results; however, evaluation of the potential for recall bias in case--control studies of pesticides among farmers has not uncovered evidence that it occurred ([@b3-ehp0113-000049]).

Our finding of a suggested association of multiple myeloma incidence with glyphosate exposure has not been previously reported, although numerous studies have observed increased myeloma risk associated with farming occupation ([@b4-ehp0113-000049]; [@b6-ehp0113-000049]; [@b7-ehp0113-000049]; [@b8-ehp0113-000049]; [@b9-ehp0113-000049]; [@b17-ehp0113-000049]; [@b18-ehp0113-000049]; [@b20-ehp0113-000049]; [@b28-ehp0113-000049]; [@b36-ehp0113-000049] [@b37-ehp0113-000049]; [@b41-ehp0113-000049]; [@b42-ehp0113-000049]; [@b44-ehp0113-000049]; [@b46-ehp0113-000049]; [@b49-ehp0113-000049]). A possible biologic mechanism of how glyphosate might act along the causal pathway of this plasma cell cancer has not been hypothesized, but myeloma has been associated with agents that cause either DNA damage or immunosuppression ([@b11-ehp0113-000049]). The association we observed was with ever use of glyphosate and cumulative exposure days of use (a combination of duration and frequency), but not with intensity of exposure. Estimated intensity of glyphosate exposure was based on general work practices that were not glyphosate specific, including the percentage of time spent mixing and applying pesticides, application method, use of personal protective equipment, and repair of pesticide application equipment ([@b13-ehp0113-000049]). Information on work practices specific to glyphosate use would clarify whether intensity of exposure contributes to myeloma risk.

The number of myeloma cases in our study was small, and it is plausible that spurious associations arose by chance; however, several aspects of our results argue against a chance association. The findings were internally consistent, with increased risk observed in both states. Adding to the credibility of the association, there was some indication of a dose--response relationship, with risk estimates increasing across categories of increasing exposure and stronger associations observed when using never-exposed subjects as the referent (as opposed to low exposed). Another possible explanation for spurious associations is unadjusted confounding. Our risk estimates were adjusted for some demographic and lifestyle factors and other pesticides. Of the other pesticides included in the fully adjusted model, only diazinon and trifluralin were important confounders of the glyphosate--myeloma association. It is certainly possible that an unknown risk factor for myeloma could have confounded our results; however, any unknown confounder would have to be linked with glyphosate use. Finally, the increased myeloma risk associated with glyphosate use could be due to bias resulting from a selection of subjects in adjusted analyses that differed from subjects included in unadjusted analyses. [Table 1](#t1-ehp0113-000049){ref-type="table"} shows that 54,315 subjects were included in age-adjusted models, whereas because of missing data for covariates, only 40,719 subjects were included in fully adjusted analyses. The association of glyphosate with myeloma differed between the two groups, even without adjustment for any covariates, with no association among the full group and a positive association among the more restricted group. Subjects who answered all the questions and were thus included in adjusted analyses differed from those who dropped out of such analyses in that they were more likely to be from Iowa (71.8% in included group vs. 44.6% in dropped group), were younger (average age, 51.5 vs. 57.9 years), and were more highly educated (46.7% educated beyond high school graduate vs. 30.2%); however, the two groups were similar in their use of glyphosate (75.9% vs. 74.5%). The increased risk associated with glyphosate in adjusted analyses may be due to selection bias or could be due to a confounder or effect modifier that is more prevalent among this restricted subgroup and is unaccounted for in our analyses. Further follow-up of the cohort and reevaluation of the association between glyphosate exposure and myeloma incidence after a greater number of cases develop will allow more detailed examination of the potential biases underlying the association.

Certain limitations of our data hinder the inferences we can make regarding glyphosate and its association with specific cancer subtypes. Although the AHS cohort is large, and there were many participants reporting glyphosate use, the small numbers of specific cancers occurring during the follow-up period hindered precise effect estimation. In addition, most applicators were male, precluding our ability to assess the association between glyphosate exposure and cancer incidence among women, for both non-sex-specific cancers and sex-specific cancers (e.g., of the breast or ovary). Our analysis provides no information on the timing of pesticide use in relation to disease, limiting the ability to sufficiently explore latency periods or effects resulting from glyphosate exposure at different ages. Despite limitations of our study, certain inferences are possible. This prospective study of cancer incidence provided evidence of no association between glyphosate exposure and most of the cancers we studied, and a suggested association between glyphosate and the risk of multiple myeloma. Future analyses within the AHS will follow up on these findings and will examine associations between glyphosate exposure and incidence of less common cancers.

###### 

Selected characteristics of applicators in the AHS by glyphosate exposure, based on data from the enrollment questionnaire (1993--1997).[*^a^*](#tfn1-ehp0113-000049){ref-type="table-fn"}

                                                                      Never exposed (*n* = 13,280)   Never exposed (*n* = 15,911)[*^b^*](#tfn2-ehp0113-000049){ref-type="table-fn"}   Higher exposed (*n* = 24,465)[*^c^*](#tfn3-ehp0113-000049){ref-type="table-fn"}
  ------------------------------------------------------------------- ------------------------------ -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  State of residence                                                                                                                                                                  
   Iowa                                                               9,987 (75.2)                   9,785 (61.5)                                                                     15,336 (62.7)
   North Carolina                                                     3,293 (24.8)                   6,126 (38.5)                                                                     9,129 (37.3)
  Age (years)                                                                                                                                                                         
   \< 40                                                              2,279 (17.2)                   2,226 (14.0)                                                                     4,190 (17.1)
   40--49                                                             3,420 (25.8)                   4,279 (26.9)                                                                     7,899 (32.3)
   50--59                                                             2,989 (22.5)                   3,931 (24.7)                                                                     6,035 (24.7)
   60--69                                                             2,715 (20.4)                   3,266 (20.5)                                                                     3,997 (16.3)
   70                                                                 1,877 (14.1)                   2,209 (13.9)                                                                     2,344 (9.6)
  Sex                                                                                                                                                                                 
   Male                                                               12,778 (96.2)                  15,505 (97.5)                                                                    23,924 (97.8)
   Female                                                             502 (3.8)                      406 (2.6)                                                                        541 (2.2)
  Applicator type[*^d^*](#tfn4-ehp0113-000049){ref-type="table-fn"}                                                                                                                   
   Private                                                            12,067 (90.9)                  15,008 (94.3)                                                                    21,938 (89.7)
   Commercial                                                         1,213 (9.1)                    903 (5.7)                                                                        2,527 (10.3)
  Education                                                                                                                                                                           
   High school graduate or GED                                        8,898 (68.7)                   8,997 (57.9)                                                                     11,975 (50.1)
   Beyond high school                                                 4,060 (31.3)                   6,530 (42.1)                                                                     11,936 (49.9)
  Smoking history                                                                                                                                                                     
   Never                                                              7,298 (57.3)                   8,241 (53.2)                                                                     12,751 (53.7)
   ≤ 12 pack-years                                                    2,866 (22.5)                   3,597 (23.2)                                                                     5,572 (23.5)
   \> 12 pack-years                                                   2,567 (20.2)                   3,643 (23.5)                                                                     5,439 (22.9)
  Alcohol consumption in past year                                                                                                                                                    
   None                                                               4,087 (32.7)                   5,352 (35.6)                                                                     7,023 (29.8)
   ≤ 6 drinks/month                                                   4,461 (35.7)                   5,291 (35.2)                                                                     8,149 (34.5)
   \> 6 drinks/month                                                  3,936 (31.5)                   4,387 (29.2)                                                                     8,422 (35.7)
  Family history of cancer                                                                                                                                                            
   No                                                                 8,701 (65.5)                   9,520 (59.8)                                                                     14,668 (60.0)
   Yes                                                                4,579 (34.5)                   6,391 (40.2)                                                                     9,797 (40.0)
  Use of other common pesticides                                                                                                                                                      
   2,4-D                                                              7,030 (53.3)                   11,879 (75.2)                                                                    20,699 (85.1)
   Alachlor                                                           4,896 (39.7)                   7,321 (50.9)                                                                     13,790 (59.7)
   Atrazine                                                           7,707 (58.5)                   10,533 (66.6)                                                                    18,237 (75.0)
   Metolachlor                                                        3,890 (31.6)                   6,172 (43.1)                                                                     12,952 (56.2)
   Trifluralin                                                        4,239 (34.0)                   7,109 (49.7)                                                                     14,675 (63.5)
   Carbaryl                                                           4,110 (33.7)                   8,515 (58.1)                                                                     15,139 (64.8)
   Benomyl                                                            510 (4.3)                      1,418 (9.9)                                                                      3,391 (14.8)
   Maneb                                                              492 (4.1)                      1,412 (9.9)                                                                      2,929 (12.9)
   Paraquat                                                           1,067 (9.0)                    3,021 (21.2)                                                                     8,031 (35.2)
   Diazinon                                                           1,906 (16.0)                   4,615 (32.4)                                                                     9,107 (40.0)

Includes observations for subjects included in age-adjusted Poisson regression models of cancer incidence (*n* = 54,315).

Lowest tertile of cumulative exposure days.

Highest two tertiles of cumulative exposure days; the sum of the three tertiles of cumulative exposure days (*n* = 40,376) does not equal the total number of subjects who reported having ever used glyphosate (*n* = 41,035) because of missing data on duration and frequency of use.

"Private" refers primarily to individual farmers, and "commercial" refers to professional pesticide applicators.

###### 

Association of glyphosate exposure (ever/never used) with common cancers[*^a^*](#tfn5-ehp0113-000049){ref-type="table-fn"} among AHS applicators.

                                                   RR (95% CI)[*^b^*](#tfn6-ehp0113-000049){ref-type="table-fn"}   
  --------------------------------- ------- ------ --------------------------------------------------------------- -------------------------------------------------------------------
  All cancers                       2,088   73.6   1.0 (0.9--1.1)                                                  1.0 (0.9--1.2)
  Lung                              204     72.1   1.0 (0.7--1.3)                                                  0.9 (0.6--1.3)
  Oral cavity                       59      76.3   1.1 (0.6--2.0)                                                  1.0 (0.5--1.8)
  Colon                             174     75.3   1.1 (0.8--1.6)                                                  1.4 (0.8--2.2)[*^e^*](#tfn9-ehp0113-000049){ref-type="table-fn"}
  Rectum                            76      77.6   1.2 (0.7--2.1)                                                  1.3 (0.7--2.3)
  Pancreas                          38      76.3   1.2 (0.6--2.5)                                                  0.7 (0.3--2.0)[*^e^*](#tfn9-ehp0113-000049){ref-type="table-fn"}
  Kidney                            63      73.0   1.0 (0.6--1.7)                                                  1.6 (0.7--3.8)[*^e^*](#tfn9-ehp0113-000049){ref-type="table-fn"}
  Bladder                           79      76.0   1.2 (0.7--2.0)                                                  1.5 (0.7--3.2)[*^e^*](#tfn9-ehp0113-000049){ref-type="table-fn"}
  Prostate                          825     72.5   1.0 (0.8--1.1)                                                  1.1 (0.9--1.3)
  Melanoma                          75      84.0   1.8 (1.0--3.4)                                                  1.6 (0.8--3.0)
  All lymphohematopoietic cancers   190     75.3   1.1 (0.8--1.5)                                                  1.1 (0.8--1.6)
  NHL                               92      77.2   1.2 (0.7--1.9)                                                  1.1 (0.7--1.9)
  Leukemia                          57      75.4   1.1 (0.6--2.0)                                                  1.0 (0.5--1.9)
  Multiple myeloma                  32      75.0   1.1 (0.5--2.4)                                                  2.6 (0.7--9.4)[*^f^*](#tfn10-ehp0113-000049){ref-type="table-fn"}

Cancers for which at least 30 subjects had sufficient information for inclusion in age-adjusted analyses.

RRs and 95% CIs from Poisson regression models.

Frequencies among subjects included in age-adjusted analyses.

Numbers of subjects in these analyses are lower than in age-adjusted analyses because of missing observations for some covariates (models adjusted for demographic and lifestyle factors include 49,211 subjects; models additionally adjusted for other pesticides include 40,719 subjects).

Estimates adjusted for other pesticides are shown because inclusion of other pesticide variables in the model changed the effect estimate for glyphosate by at least 20%.

The estimate for myeloma was not confounded by other pesticides according to our change-in-estimate rule of ≥20%; however, the fully adjusted estimate is shown for the purpose of comparison with state-specific estimates (in the text), which were confounded by other pesticides and required adjustment.

###### 

Association of glyphosate exposure (cumulative exposure days and intensity-weighted exposure days) with common cancers[*^a^*](#tfn11-ehp0113-000049){ref-type="table-fn"} among AHS applicators.

                                    Cumulative exposure days[*^b^*](#tfn12-ehp0113-000049){ref-type="table-fn"}   Intensity-weighted exposure days[*^c^*](#tfn13-ehp0113-000049){ref-type="table-fn"}                                                                                                                                                                        
  --------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------ --------------- ----- ------------------------------------------------------------------- ------
  All cancers                       1--20                                                                         594                                                                                   1.0                                                                        0.1--79.5       435   1.0                                                                 
                                    21--56                                                                        372                                                                                   1.0 (0.9--1.1)                                                             79.6--337.1     436   0.9 (0.8--1.0)                                                      
                                    57--2,678                                                                     358                                                                                   1.0 (0.9--1.1)                                                      0.57   337.2--18,241   438   0.9 (0.8--1.1)                                                      0.35
  Lung                              1--20                                                                         40                                                                                    1.0                                                                        0.1--79.5       27    1.0                                                                 
                                    21--56                                                                        26                                                                                    0.9 (0.5--1.5)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}          79.6--337.1     38    1.1 (0.7--1.9)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   
                                    57--2,678                                                                     26                                                                                    0.7 (0.4--1.2)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   0.21   337.2--18,241   27    0.6 (0.3--1.0)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   0.02
  Oral cavity                       1--20                                                                         18                                                                                    1.0                                                                        0.1--79.5       11    1.0                                                                 
                                    21--56                                                                        10                                                                                    0.8 (0.4--1.7)                                                             79.6--337.1     14    1.1 (0.5--2.5)                                                      
                                    57--2,678                                                                     10                                                                                    0.8 (0.4--1.7)                                                      0.66   337.2--18,241   13    1.0 (0.5--2.3)                                                      0.95
  Colon                             1--20                                                                         32                                                                                    1.0                                                                        0.1--79.5       25    1.0                                                                 
                                    21--56                                                                        28                                                                                    1.4 (0.9--2.4)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}          79.6--337.1     20    0.8 (0.5--1.5)[*^c^*](#tfn13-ehp0113-000049){ref-type="table-fn"}   
                                    57--2,678                                                                     15                                                                                    0.9 (0.4--1.7)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   0.54   337.2--18,241   30    1.4 (0.8--2.5)[*^c^*](#tfn13-ehp0113-000049){ref-type="table-fn"}   0.10
  Rectum                            1--20                                                                         20                                                                                    1.0                                                                        0.1--79.5       16    1.0                                                                 
                                    21--56                                                                        17                                                                                    1.3 (0.7--2.5)                                                             79.6--337.1     18    1.0 (0.5--2.0)                                                      
                                    57--2,678                                                                     14                                                                                    1.1 (0.6--2.3)                                                      0.70   337.2--18,241   16    0.9 (0.5--1.9)                                                      0.82
  Pancreas                          0--20                                                                         9                                                                                     1.0                                                                        0--79.5         6     1.0                                                                 
                                    21--56                                                                        9                                                                                     1.6 (0.6--4.1)                                                             79.6--337.1     16    2.5 (1.0--6.3)                                                      
                                    57--2,678                                                                     7                                                                                     1.3 (0.5--3.6)                                                      0.83   337.2--18,241   3     0.5 (0.1--1.9)                                                      0.06
  Kidney                            1--20                                                                         20                                                                                    1.0                                                                        0.1--79.5       20    1.0                                                                 
                                    21--56                                                                        8                                                                                     0.6 (0.3--1.4)                                                             79.6--337.1     7     0.3 (0.1--0.7)                                                      
                                    57--2,678                                                                     9                                                                                     0.7 (0.3--1.6)                                                      0.34   337.2--18,241   10    0.5 (0.2--1.0)                                                      0.15
  Bladder                           1--20                                                                         23                                                                                    1.0                                                                        0.1--79.5       14    1.0                                                                 
                                    21--56                                                                        14                                                                                    1.0 (0.5--1.9)                                                             79.6--337.1     8     0.5 (0.2--1.3)                                                      
                                    57--2,678                                                                     17                                                                                    1.2 (0.6--2.2)                                                      0.53   337.2--18,241   13    0.8 (0.3--1.8)                                                      0.88
  Prostate                          1--20                                                                         239                                                                                   1.0                                                                        0.1--79.5       167   1.0                                                                 
                                    21--56                                                                        132                                                                                   0.9 (0.7--1.1)                                                             79.6--337.1     169   1.0 (0.8--1.2)                                                      
                                    57--2,678                                                                     145                                                                                   1.1 (0.9--1.3)                                                      0.69   337.2--18,241   174   1.1 (0.9--1.3)                                                      0.60
  Melanoma                          1--20                                                                         23                                                                                    1.0                                                                        0.1--79.5       24    1.0                                                                 
                                    21--56                                                                        20                                                                                    1.2 (0.7--2.3)                                                             79.6--337.1     16    0.6 (0.3--1.1)                                                      
                                    57--2,678                                                                     14                                                                                    0.9 (0.5--1.8)                                                      0.77   337.2--18,241   17    0.7 (0.3--1.2)                                                      0.44
  All lymphohematopoietic cancers   1--20                                                                         48                                                                                    1.0                                                                        0.1--79.5       38    1.0                                                                 
                                    21--56                                                                        38                                                                                    1.2 (0.8--1.8)                                                             79.6--337.1     40    1.0 (0.6--1.5)                                                      
                                    57--2,678                                                                     36                                                                                    1.2 (0.8--1.8)                                                      0.69   337.2--18,241   43    1.0 (0.7--1.6)                                                      0.90
  NHL                               1--20                                                                         29                                                                                    1.0                                                                        0.1--79.5       24    1.0                                                                 
                                    21--56                                                                        15                                                                                    0.7 (0.4--1.4)                                                             79.6--337.1     15    0.6 (0.3--1.1)                                                      
                                    57--2,678                                                                     17                                                                                    0.9 (0.5--1.6)                                                      0.73   337.2--18,241   22    0.8 (0.5--1.4)                                                      0.99
  Leukemia                          1--20                                                                         9                                                                                     1.0                                                                        0.1--79.5       7     1.0                                                                 
                                    21--56                                                                        14                                                                                    1.9 (0.8--4.5)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}          79.6--337.1     17    1.9 (0.8--4.7)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   
                                    57--2,678                                                                     9                                                                                     1.0 (0.4--2.9)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   0.61   337.2--18,241   8     0.7 (0.2--2.1)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   0.11
  Multiple myeloma                  1--20                                                                         8                                                                                     1.0                                                                        0--79.5         5     1.0                                                                 
                                    21--56                                                                        5                                                                                     1.1 (0.4--3.5)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}          79.6--337.1     6     1.2 (0.4--3.8)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   
                                    57--2,678                                                                     6                                                                                     1.9 (0.6--6.3)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   0.27   337.2--18,241   8     2.1 (0.6--7.0)[*^e^*](#tfn15-ehp0113-000049){ref-type="table-fn"}   0.17

Cancers for which at least 30 subjects had sufficient information for inclusion in age-adjusted analyses.

Numbers of subjects in analyses vary depending on missing observations for cumulative exposure days and some covariates (models adjusted for demographic and lifestyle factors include 36,823 subjects; models additionally adjusted for other pesticides include 30,699 subjects).

Numbers of subjects in analyses vary depending on missing observations for intensity-weighted cumulative exposure days and some covariates (models adjusted for demographic and lifestyle factors include 36,509 subjects; models additionally adjusted for other pesticides include 30,613 subjects).

Relative rate ratios and 95% CIs from Poisson regression analyses.

Estimates adjusted for other pesticides are shown because inclusion of other pesticide variables in the model changed the effect estimate for glyphosate by at least 20%.

[^1]: The authors declare they have no competing financial interests.
